PR89449

MONTREAL, May 11, 2021 /PRNewswire=KYODO JBN/ --

CellCarta, a global provider of precision medicine services, announced today

the acquisition of Reveal Biosciences ("Reveal"), a San Diego California based

computational pathology company offering cutting-edge artificial intelligence

(AI)-based quantitative pathology and immunohistochemistry services to the

biopharmaceutical industry. This acquisition further strengthens CellCarta's

position as a leading provider of histopathology biomarker services and will

enable the company to broaden its offering in AI-enabled multi-omic data

analysis services and applications.

Logo -

https://mma.prnewswire.com/media/1507305/CellCarta_CellCarta_Strengthens_its_Histological_Biomarker_Franc.jpg

Logo -

https://mma.prnewswire.com/media/1507125/CellCarta_CellCarta_Strengthens_its_Histological_Biomarker_Franc.jpg

Reveal Biosciences has created a new generation of Pathology Intelligence(TM)

to enhance research, clinical trials, and improve patient outcomes globally.  

Reveal's imageDx(TM) pathology platform combines cutting edge machine learning

(ML)-AI with traditional histopathology to transform tissue biology into

actionable data.  Reveal's unique proprietary pipeline architecture and

biomarker-based training methods also enable the development of scalable custom

AI models for specific pathology endpoints, companion diagnostics and

predictive models integrating multi-omic data.  

"Reveal's exceptional AI and machine learning capabilities will support more

objective tissue biomarker quantitation and will enable a broader and faster

deployment of our histological services," said Martin LeBlanc, CEO of

CellCarta. "Acquiring this leading business is part of a game-changing strategy

to expand our services to better support our global clients who are actively

seeking more objective, reproducible and scalable methods for tissue biomarker

assessment, deployed within a robust quality and regulatory platform."

"We are excited to join forces with CellCarta," said Claire Weston, PhD, CEO

and Co-Founder of Reveal. "Reveal's broad portfolio of automated digital assays

target Oncology, NASH, Neuroscience, Fibrosis, Inflammation and other

therapeutic areas. We see great opportunity in combining these AI capabilities

with CellCarta driving towards better diagnoses and more meaningful clinical

trials on a global scale."

About CellCarta          

CellCarta is a leading provider of specialized precision medicine laboratory

services to the biopharmaceutical industry. Leveraging its integrated

analytical platforms in immunology, histopathology, proteomics and genomics, as

well as related specimen collection and logistics services, CellCarta supports

the entire drug development cycle, from discovery to late-stage clinical

trials. The company operates globally with 10 facilities located in Canada,

USA, Belgium, Australia, and China.

For more information: www.cellcarta.com

About Reveal Biosciences      

Reveal Biosciences has created a new generation of Pathology Intelligence(TM)

to enhance research and improve patient outcomes globally.  Reveal's

imageDx(TM) pathology platform provides AI data analytics and cloud-based whole

slide image management to Life Sciences and Healthcare.  With a world class

team of data and research scientists focused on addressing some of the biggest

problems in healthcare, Reveal has developed a pipeline of AI-based digital

assays for preclinical research, clinical trials, and diagnostics.  

For more information: http://revealbio.com  

Media Contact for CellCarta: Prosek Partners, Brian Schaffer / Kristen Duarte,

bschaffer@prosek.com / kduarte@prosek.com; Marketing & Communications: Guylaine

Galipeau, Global Marketing Director, CellCarta, ggalipeau@caprion.com

SOURCE: CellCarta